Background: Thrombosis within a left ventricular assist device (LVAD) is a devastating
pump thrombosis requires high-dose anticoagulation, pump exchange, or urgent transplantation. 5, 6 In those patients who are unable to undergo an exchange or transplantation there is an observed mortality of 48.2% at 6 months. 1 In 2011, there was a significant increase in the rate of pump thrombosis associated with the HeartMate II (HM2) device (Thoratec, Pleasanton, CA). 3, 5 As a result, close attention has been given to factors that may lead to pump thrombosis including implantation technique. Careful intraoperative positioning has been highlighted as a key component of optimal therapy. Several studies have demonstrated that pump malposition may contribute to pump thrombosis. 7, 8 The ideal inflow cannula placement is parallel to the septum and oriented to the central left ventricle. Sorensen et al 9 note that in post-implantation imaging over 50% of patients exhibit some form of cannula malposition.
Most studies have concluded that improved surgical technique is the answer to appropriate pump placement. 7, 10, 11 However, even with meticulous technique, there are some patients in whom anatomic factors make it more difficult to obtain and subsequently maintain the ideal pump placement with the HeartMate II device. 9 The purpose of this study was to determine the reproducibility and impact of left ventricular angle (LV angle) measurement in predicting pump thrombosis after HM2 implantation. We hypothesized that a laterally displaced left ventricular apex would correlate with increased risk of pump thrombosis and need for exchange. 
| Measures
Patients were stratified by development of presumed pump thrombo- analyzed the impact of LV apex angle on risk for pump exchange due to thrombosis. All analysis was performed using SAS Version 9.4 (SAS Institute, Cary, NC) with statistical significant set at a P-value of 0.05.
3 | RESULTS
| Measurements
The mean LV apex angle calculated by surgeon A was 46.0 ± 10.7°w
hile the mean angle for surgeon B was 43.1 ± 10.0°. These demonstrated a high level of inter-observer reliability as seen in Figure 1B with Pearson Correlation Coefficient of 0.893.
| Patient characteristics
Patient demographics and preoperative characteristics were largely similar between cohorts as presented in Table 1 . The median age was 59, 24.6% were female, and the mean LV angle was 44.6°. There were no statistically different preoperative characteristics between those with pump thrombosis compared to those without thrombosis, except for LV angle, which was significantly greater in the pump thrombosis cohort (49.5 ± 11.2 versus 43.8 ± 9.7, P = 0.037). Operative characteristics were also similar between groups as shown in Table 2 . When we defined early thrombosis as those patients who required a pump exchange within a year of primary implant, we found that the patients with the greater preoperative LV angle were more likely to require early pump exchange ( Figure 2 ). This was statistically significant when compared to the group with no pump thrombosis as well as when compared to those with a late pump thrombosis. Lastly, Figure 3 demonstrates the mean angle for patients with multiple thrombosis events was significantly greater compared to those without pump thrombosis (56.3 vs 43.9, P = 0.02).
| Outcomes
For the entire cohort, the operative mortality rate was 0.8%, major morbidity 48.7%, and post-operative length of stay was a median of 20 days. Short-term outcomes were similar between groups without any statistically significant differences (Table 3 ). There was a trend toward a higher rate of reoperation in patients with pump thrombosis (43.8% vs 
| DISCUSSION
This study demonstrates a more laterally displaced LV is correlated with pump thrombosis and need for pump exchange in patients with a HM2 LVAD. Furthermore, these patients were more likely to require an early pump exchange within 1 year of primary Late pump thrombosis is primarily driven by pump migration and other hemodynamic factors. Of note, no increased hypercoaguability was noted in our patient cohort.
It is our practice to support the patient with cardiopulmonary bypass during LVAD placement. We cross clamp the heart in the setting of valve repair/replacement or patent foramen ovale closure.
Pre-existing thrombus is removed in all cases and a cross clamp is not 
FIGURE 2
Patients who underwent a pump exchange for presumed pump thrombosis within 1 year of primary implantation had a significantly greater LV angle. LV, left ventricular
FIGURE 3
Patient who underwent multiple LVAD exchanges for pump thrombosis in this study were found to have the greatest LV angle. LV, left ventricular; LVAD, LV assist device specifically used for that purpose at our institution. This study population demonstrated no difference in preoperative atrial fibrillation but we do not perform atrial appendage ligation for these patients.
Pump exchange has been shown to decrease mortality associated with pump thrombosis and is the preferred strategy for management of pump thrombosis at our institution in view of the advantages and disadvantages of anticoagulation therapy in these high-risk patients. 16 Similar to other centers, we use an elevated LDH as well as signs of LVAD malfunction as criteria for pump exchange. 13, [17] [18] [19] For HM2
exchange we use a subcostal incision for pump only exchange. We bleed the inflow and outflow grafts to ensure these are free of thrombus. In the early years of this study, not all devices were returned for inspection. However in those patients in whom the pump was returned to the company for inspection, all had a confirmed thrombus within the pump. In all patients in this cohort, HM2 devices were exchanged for another HM2. Given the findings of this study, in patients with a greater LV angle, consideration for exchange to a different device should be considered, as the risk for subsequent pump thrombosis may be high.
The limitations of this study include the single center retrospective nature in addition to only obtaining one anatomic measurement. While this was a statistically significant predictor of pump thrombosis there are a number of patients with a laterally displaced LV who did not have pump thrombosis. There are likely several anatomic factors such as central obesity as well as non-anatomic factors that may have contributed to pump thrombosis. 5, 8, 19 Finally, this study is limited to patients who underwent a pump exchange for presumed pump thrombosis. As a center, we are aggressive about early LVAD replacement for presumed pump thrombosis and if someone is admitted with clinical symptoms and elevated LDH refractory to medical therapy we almost always operate. However, due to study design we are unable to identify individuals who may have had pump thrombosis but were managed medically. Therefore, our data may underestimate the incidence of pump thrombosis.
In conclusion, the HM2 device has long-term proven results and, until recently, was one of the only durable left ventricular assist devices approved in the United States. 20 For that reason, studies revolved around how to optimize this pump for all patients with advanced heart failure. The findings in this study demonstrate that there is a higher rate of pump thrombosis with the HM2 in those patients with the most laterally displaced LV apex despite proper positioning on postoperative chest radiograph. With the advent of implantable intrapericardial devices, there are now options for which device to implant. While LVAD selection is still driven largely by a patient's transplant status as well as insurance designation, we have used the data from this study as reason to consider patient anatomy when selecting a device.
Continued follow-up is necessary to determine if a tailored approach based on patient anatomic features will decrease the incidence of pump thrombosis.
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